i 191

I-191 is a potent antagonist of protease-activated receptor 2 (PAR2), inhibits multiple signaling functions in human cancer cells.

BI-1915 is a selective inhibitor of Cathepsin S, with an IC50 of 17 nM. It is utilized in the research of autoimmune diseases.

TPI-1917-49 is a promising amyloid reducing agent that works by reducing Aβ levels.

MEDI-1912 is a human monoclonal antibody targeting NGF/bNGF. It inhibits signaling via the TrkA and p75 receptors and can be utilized in chronic pain research.

BI-1910 is a human monoclonal antibody (mAb) targeting TNFRSF1B. It enhances T cell activation and induces CD8 T cell-dependent anti-tumor activity. BI-1910 is applicable for research on solid tumors. Recommended isotype control: HumanIgG1lambda, Isotype Control.

D-threo-PPMP is a glucosylceramide (GlyCer) synthetase inhibitor.1,2It is the active enanantiomer and enzymatic inhibitory component of the racemic DL-threo-PPMP . In MDCK kidney epithelial cells, D-threo-PPMP induces a 70% reduction in cell growthin vitroat 20 μM and significantly inhibits DNA synthesis at 3 μM.3[Matreya, LLC. Catalog No. 1865] 1.Shen, W., Henry, A.G., Paumier, K.L., et al.Inhibition of glucosylceramide synthase stimulates autophagy flux in neuronsJ. Neurochem.129(5)884-894(2014) 2.Lee, L., Abe, A., and Shayman, J.A.Improved inhibitors of glucosylceramide synthaseJ. Biol. Chem.274(21)14662-14669(1999) 3.Abe, A., Inokuchi, J.-i., Jimbo, M., et al.Improved inhibitors of glucosylceramide synthaseJ. Biochem.111(2)191-196(1992)